(Q38710509)

5 September 2017

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes (English)

1 reference

5 September 2017

acute myeloid leukemia

1 reference

4

1 reference

5 September 2017

Maximilian Stahl

1

1 reference

5 September 2017

Steven D Gore

series ordinal

2

1 reference

5 September 2017

Norbert Vey

series ordinal

3

1 reference

5 September 2017

language of work or name

English

0 references

publication date

25 January 2016

1 reference

Expert Opinion on Investigational Drugs

5 September 2017

1 reference

5 September 2017

25

1 reference

5 September 2017

3

1 reference

5 September 2017

307-317

1 reference

Epigenetic deregulation in myeloid malignancies.

5 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

CpG-rich islands and the function of DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

New and emerging HDAC inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Deacetylation of nonhistone proteins by HDACs and the implications in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Nonhistone protein acetylation as cancer therapy targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

A phase 2 study of vorinostat in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Translating the histone code into leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Deacetylation of p53 modulates its effect on cell growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Targeting tumor angiogenesis with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Histone deacetylases as regulators of inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

The anticancer effects of HDAC inhibitors require the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Deacetylase inhibition promotes the generation and function of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

HDAC inhibitors and immunotherapy; a double edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Hdac3 is essential for the maintenance of chromatin structure and genome stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

Myelodysplastic syndromes standardized response criteria: further definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1146251

10.1517/13543784.2016.1146251

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference